Trial intelligence / Profile preview

MYCrocytic: IDP-121 plus chemotherapy in relapsed small cell lung cancer

2025-521902-17-00Phase 2Authorised

Sponsor: IDP Discovery Pharma
Start: Dec 2025
Modality: Peptides
Countries: 1

Overview

Phase 2, open-label trial of IDP-121 in small cell lung cancer (SCLC) (2 arms), sponsored by IDP Discovery Pharma. Planned start Dec 2025; status: authorised.

Drugs

IDP-121

Conditions

small cell lung cancer (SCLC)

Beyond the preview

Go deeper on 2025-521902-17-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2025-521902-17-00.